StoryRegulatory
Blindsight receives FDA Breakthrough Device designation
Neuralink announced that the FDA granted Breakthrough Device Designation to Blindsight, its implant intended for people with vision impairment or blindness. The designation expedites FDA review and indicates the device has potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions. Neuralink opened its patient registry to candidates and set expectations that initial vision would resemble low-resolution Atari-era graphics with potential for future enhancement.
- Breakthrough Device Designation speeds development and review timeline; applies to implants restoring vision in people who have lost both eyes and optic nerve (but retain intact visual cortex).
- Elon Musk stated potential to eventually exceed natural vision resolution and enable new modalities like infrared, ultraviolet or radar wavelengths visualization.
- Initial vision capability set to low resolution; patient registry launched ahead of clinical trial initiation.